Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTK NASDAQ:IBRX NASDAQ:MESO NASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$77.89+4.8%$64.21$29.31▼$80.20$9.70B0.382.15 million shs850,702 shsIBRXImmunityBio$7.87+1.4%$8.00$1.95▼$12.43$8.30B0.0231.24 million shs3.18 million shsMESOMesoblast$14.68-0.8%$15.20$9.88▼$21.50$1.90B2.09241,022 shs34,246 shsNUVLNuvalent$104.86+2.4%$101.94$68.64▼$113.01$8.26B1.15560,693 shs99,948 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics-0.73%+16.13%+13.45%+19.17%+124.85%IBRXImmunityBio-7.40%+9.30%+13.12%+28.26%+310.58%MESOMesoblast-6.39%-5.55%+8.11%-7.21%+33.94%NUVLNuvalent-1.78%+2.11%+0.15%-1.15%+53.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$77.89+4.8%$64.21$29.31▼$80.20$9.70B0.382.15 million shs850,702 shsIBRXImmunityBio$7.87+1.4%$8.00$1.95▼$12.43$8.30B0.0231.24 million shs3.18 million shsMESOMesoblast$14.68-0.8%$15.20$9.88▼$21.50$1.90B2.09241,022 shs34,246 shsNUVLNuvalent$104.86+2.4%$101.94$68.64▼$113.01$8.26B1.15560,693 shs99,948 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics-0.73%+16.13%+13.45%+19.17%+124.85%IBRXImmunityBio-7.40%+9.30%+13.12%+28.26%+310.58%MESOMesoblast-6.39%-5.55%+8.11%-7.21%+33.94%NUVLNuvalent-1.78%+2.11%+0.15%-1.15%+53.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.82Moderate Buy$97.2524.86% UpsideIBRXImmunityBio 2.86Moderate Buy$14.2080.55% UpsideMESOMesoblast 2.33HoldN/AN/ANUVLNuvalent 2.88Moderate Buy$137.2530.90% UpsideCurrent Analyst Ratings BreakdownLatest MESO, CYTK, NUVL, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026IBRXImmunityBio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$12.005/7/2026CYTKCytokinetics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$95.00 ➝ $105.005/6/2026CYTKCytokinetics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$90.00 ➝ $103.005/6/2026CYTKCytokinetics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$119.005/6/2026CYTKCytokinetics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$101.00 ➝ $119.005/6/2026CYTKCytokinetics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$98.00 ➝ $108.005/5/2026CYTKCytokinetics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$106.005/5/2026CYTKCytokinetics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$85.00 ➝ $102.005/5/2026IBRXImmunityBio D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.004/21/2026MESOMesoblast Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026NUVLNuvalent Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$88.04M110.08N/AN/A($6.64) per share-11.73IBRXImmunityBio$113.29M72.71N/AN/A($0.51) per share-15.42MESOMesoblast$65.38M29.07N/AN/A$4.67 per share3.14NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$784.96M-$6.53N/AN/AN/A-784.02%N/A-52.86%N/AIBRXImmunityBio-$351.40M-$0.38N/AN/AN/A-310.18%N/A-81.40%5/11/2026 (Estimated)MESOMesoblast-$102.14M-$0.54N/AN/AN/AN/AN/AN/AN/ANUVLNuvalent-$425.38M-$5.85N/AN/AN/AN/A-39.29%-35.01%N/ALatest MESO, CYTK, NUVL, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026IBRXImmunityBio-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million2/24/2026Q4 2025CYTKCytokinetics-$1.48-$1.50-$0.02-$1.50$8.02 million$17.76 million2/23/2026Q4 2025IBRXImmunityBio-$0.08-$0.06+$0.02-$0.06N/A$38.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokineticsN/A4.214.53IBRXImmunityBioN/A5.105.08MESOMesoblast0.101.581.41NUVLNuvalentN/A15.2715.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/AIBRXImmunityBio8.58%MESOMesoblast1.43%NUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.60%IBRXImmunityBio69.48%MESOMesoblast18.80%NUVLNuvalent10.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250124.43 million121.01 millionOptionableIBRXImmunityBio5901.05 billion319.65 millionOptionableMESOMesoblast80129.46 million105.12 millionOptionableNUVLNuvalent4078.62 million70.60 millionOptionableMESO, CYTK, NUVL, and IBRX HeadlinesRecent News About These CompaniesUBS Group AG Acquires 185,932 Shares of Nuvalent, Inc. $NUVL3 hours ago | marketbeat.comNuvalent (NASDAQ:NUVL) Announces Quarterly Earnings ResultsMay 7 at 6:30 PM | marketbeat.comNuvalent (NASDAQ:NUVL) CEO Sells $3,050,700.00 in StockMay 7 at 7:31 AM | insidertrades.comNuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial ResultsMay 7 at 6:30 AM | prnewswire.comComerica Bank Grows Holdings in Nuvalent, Inc. $NUVLMay 7 at 3:37 AM | marketbeat.comCanaccord Genuity Sticks to Their Buy Rating for Nuvalent (NUVL)May 6 at 7:42 PM | theglobeandmail.comJames Richard Porter Sells 30,000 Shares of Nuvalent (NASDAQ:NUVL) StockMay 6 at 6:06 PM | marketbeat.comNuvalent (NUVL) to Release Quarterly Earnings on ThursdayMay 6 at 4:17 AM | americanbankingnews.comNuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 6 at 3:17 AM | americanbankingnews.comNuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 6 at 3:15 AM | marketbeat.comVanguard Group Inc. Purchases 639,264 Shares of Nuvalent, Inc. $NUVLMay 5 at 8:19 AM | marketbeat.comDeborah Ann Miller Sells 5,500 Shares of Nuvalent (NASDAQ:NUVL) StockMay 3, 2026 | americanbankingnews.comInsider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 5,500 Shares of StockMay 1, 2026 | marketbeat.comNuvalent (NUVL) Submits NDA to FDA for Neladalkib in ALK-Positive NSCLCMay 1, 2026 | finance.yahoo.comNuvalent: A Precision Oncology Platform With Two Near-Term Shots On GoalApril 30, 2026 | seekingalpha.comGuardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ PlatformApril 30, 2026 | businesswire.comPictet Asset Management Holding SA Has $35.78 Million Holdings in Nuvalent, Inc. $NUVLApril 30, 2026 | marketbeat.comNuvalent (NUVL) Projected to Post Earnings on ThursdayApril 30, 2026 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Has $4.70 Million Position in Nuvalent, Inc. $NUVLApril 29, 2026 | marketbeat.comCanaccord Genuity Remains a Buy on Nuvalent (NUVL)April 24, 2026 | theglobeandmail.comAssessing Nuvalent (NUVL) Valuation After FDA Review Progress And New ALK ROS1 Trial DataApril 24, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMESO, CYTK, NUVL, and IBRX Company DescriptionsCytokinetics NASDAQ:CYTK$77.89 +3.60 (+4.85%) As of 11:28 AM Eastern This is a fair market value price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.ImmunityBio NASDAQ:IBRX$7.86 +0.11 (+1.35%) As of 11:28 AM Eastern This is a fair market value price provided by Massive. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Mesoblast NASDAQ:MESO$14.68 -0.12 (-0.78%) As of 11:28 AM Eastern This is a fair market value price provided by Massive. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Nuvalent NASDAQ:NUVL$104.86 +2.46 (+2.40%) As of 11:28 AM Eastern This is a fair market value price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
